Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Both could reward patient investors down the line.

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels.

Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ...

AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom ...

PHILADELPHIA (WPVI) -- A local researcher from Penn Medicine says there's reason to believe at least one other potential coronavirus vaccine could be as effective as Pfizer's vaccine is said to be.

President Trump said at Thursday's cabinet meeting that the deal with Pfizer to give the U.S. "most favored nation" status will substantially reduce the price of medicine. "It makes me angry," Trump ...